Prevail Therapeutics’ (PRVL) Outperform Rating Reaffirmed at Wedbush

Wedbush reiterated their outperform rating on shares of Prevail Therapeutics (NASDAQ:PRVL) in a report published on Thursday, The Fly reports. The firm currently has a $20.00 price objective on the stock, down from their prior price objective of $25.00.

Several other equities analysts also recently commented on PRVL. Morgan Stanley initiated coverage on shares of Prevail Therapeutics in a research note on Monday, July 15th. They issued an overweight rating and a $20.00 price target on the stock. Cowen initiated coverage on shares of Prevail Therapeutics in a research note on Monday, July 15th. They issued an outperform rating on the stock. Finally, Bank of America initiated coverage on shares of Prevail Therapeutics in a research note on Monday, July 15th. They issued a buy rating and a $15.00 price target on the stock.

PRVL stock opened at $10.90 on Thursday. The company has a 50-day simple moving average of $11.23. Prevail Therapeutics has a 52 week low of $7.41 and a 52 week high of $16.90.

Prevail Therapeutics (NASDAQ:PRVL) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.24) by $0.66. Research analysts anticipate that Prevail Therapeutics will post -2.51 EPS for the current fiscal year.

In other news, Director Carl L. Gordon acquired 882,352 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was acquired at an average price of $17.00 per share, with a total value of $14,999,984.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Blackstone Group Inc bought a new stake in Prevail Therapeutics during the second quarter worth about $66,000. Point72 Hong Kong Ltd bought a new stake in Prevail Therapeutics during the second quarter worth about $106,000. Morgan Stanley bought a new stake in Prevail Therapeutics during the second quarter worth about $166,000. Northern Trust Corp bought a new stake in Prevail Therapeutics during the second quarter worth about $188,000. Finally, SG Americas Securities LLC bought a new stake in Prevail Therapeutics during the second quarter worth about $194,000. 0.17% of the stock is owned by institutional investors and hedge funds.

About Prevail Therapeutics

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Recommended Story: Ex-Dividend

The Fly

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.